Klotho Neurosciences Reports Q3 2025 Financial Results with $2.9 Million Net Loss

Klotho Neurosciences, Inc. reported its financial results for the third quarter of 2025, revealing a net loss of $2.9 million, a slight decrease from the $2.96 million loss recorded in the same period of 2024. For the nine months ending September 30, 2025, the company experienced a net loss of $9.22 million, compared to a loss of $4.08 million for the same period in the previous year. The company has not generated any revenue during these periods, as it remains in a pre-revenue state while developing its product offerings.

Total operating expenses for the third quarter of 2025 were approximately $1.85 million, down from $2.87 million in the prior year, primarily due to reductions in share-based compensation and professional fees. However, the nine-month operating expenses increased to $5.33 million from $3.69 million, driven by higher professional fees, general and administrative costs, and research and development expenditures. The company reported cash and cash equivalents of $7.35 million as of September 30, 2025, a significant increase from $63,741 at the end of 2024, largely due to financing activities.

Klotho's strategic developments included the completion of a business combination with Redwoods Acquisition Corp. in June 2024, which was treated as a reverse acquisition for accounting purposes. The company has also been active in raising capital, securing $11.89 million in financing during the first nine months of 2025, compared to $2.17 million in the same period of 2024. This funding was sourced from various equity and debt instruments, including the issuance of common and preferred shares.

Operationally, Klotho has focused on expanding its product pipeline, which includes a generic drug portfolio and a biosimilar biologics platform. The company has also made significant investments in research and development, with R&D expenses amounting to $271,145 for the third quarter of 2025, compared to no R&D expenses in the same quarter of 2024. The company’s employee headcount has increased as it continues to build its operational capabilities.

Looking ahead, Klotho has expressed concerns regarding its ability to continue as a going concern, citing the need for additional funding to support its operations and development plans. The company is currently working to regain compliance with Nasdaq listing requirements after receiving a notification for failing to maintain a minimum bid price for its common stock. Klotho's management remains focused on executing its strategic initiatives while navigating the challenges of the biotechnology sector.